{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T19:57:06Z","timestamp":1790193426680,"version":"4.1.0"},"reference-count":101,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T00:00:00Z","timestamp":1760918400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["iLIVER"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.iliver.2025.100197","type":"journal-article","created":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T06:59:54Z","timestamp":1761375594000},"page":"100197","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["From thrombosis to transplantation: The role of anti-phospholipid antibodies in liver disease management"],"prefix":"10.1016","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3734-3253","authenticated-orcid":false,"given":"Dante Pio","family":"Pallotta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenio","family":"Franceschini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Boe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5521-270X","authenticated-orcid":false,"given":"Agnese","family":"Pratelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Monaco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"De Sinno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0637-739X","authenticated-orcid":false,"given":"Alessandro","family":"Granito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.iliver.2025.100197_bib1","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s10557-023-07496-3","article-title":"Antiphospholipid syndrome: state of the art of clinical management","volume":"39","author":"Depietri","year":"2025","journal-title":"Cardiovasc Drugs Ther"},{"issue":"10","key":"10.1016\/j.iliver.2025.100197_bib2","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1136\/ard-2023-224609","article-title":"2023 ACR\/EULAR antiphospholipid syndrome classification criteria","volume":"82","author":"Barbhaiya","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.iliver.2025.100197_bib3","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1002\/1529-0131(199907)42:7<1309::AID-ANR1>3.0.CO;2-F","article-title":"International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop","volume":"42","author":"Wilson","year":"1999","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.iliver.2025.100197_bib4","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","article-title":"International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)","volume":"4","author":"Miyakis","year":"2006","journal-title":"J Thromb Haemost"},{"issue":"Suppl 1","key":"10.1016\/j.iliver.2025.100197_bib5","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/ijlh.13195","article-title":"Testing for antiphospholipid antibodies: advances and best practices","volume":"42","author":"Devreese","year":"2020","journal-title":"Int J Lab Hematol"},{"issue":"8","key":"10.1016\/j.iliver.2025.100197_bib6","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s11926-020-00916-5","article-title":"How to interpret antiphospholipid laboratory tests","volume":"22","author":"Devreese","year":"2020","journal-title":"Curr Rheumatol Rep"},{"issue":"SI","key":"10.1016\/j.iliver.2025.100197_bib7","doi-asserted-by":"crossref","first-page":"SI64","DOI":"10.1093\/rheumatology\/kead632","article-title":"Viewpoint: the value of non-criteria antiphospholipid antibodies","volume":"63","author":"de Laat","year":"2024","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"10.1016\/j.iliver.2025.100197_bib8","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1111\/jth.14765","article-title":"Tetra positive thrombotic antiphospholipid syndrome: major contribution of anti-phosphatidyl-serine\/prothrombin antibodies to lupus anticoagulant activity","volume":"18","author":"Cattini","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"23","key":"10.1016\/j.iliver.2025.100197_bib9","doi-asserted-by":"crossref","first-page":"8972","DOI":"10.3390\/ijms21238972","article-title":"The weight of IgA Anti-\u03b22glycoprotein I in the antiphospholipid syndrome pathogenesis: closing the gap of seronegative antiphospholipid syndrome","volume":"21","author":"Cabrera-Marante","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.iliver.2025.100197_bib10","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/1471-230X-11-130","article-title":"Recipient and donor thrombophilia and the risk of portal venous thrombosis and hepatic artery thrombosis in liver recipients","volume":"11","author":"Ayala","year":"2011","journal-title":"BMC Gastroenterol"},{"issue":"6","key":"10.1016\/j.iliver.2025.100197_bib11","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/S0168-8278(98)80130-X","article-title":"Graft loss and the antiphospholipid syndrome following liver transplantation","volume":"29","author":"Collier","year":"1998","journal-title":"J Hepatol"},{"issue":"12","key":"10.1016\/j.iliver.2025.100197_bib12","doi-asserted-by":"crossref","first-page":"3530","DOI":"10.1007\/s10620-006-9356-1","article-title":"A rare association of primary biliary cirrhosis with antiphospholipid [corrected] antibody syndrome","volume":"52","author":"Gupta","year":"2007","journal-title":"Dig Dis Sci"},{"issue":"3","key":"10.1016\/j.iliver.2025.100197_bib13","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0022-2143(98)90096-8","article-title":"Prevalence of antiphospholipid antibodies in patients with chronic liver disease related to alcohol or hepatitis C virus: correlation with liver injury","volume":"131","author":"Biron","year":"1998","journal-title":"J Lab Clin Med"},{"issue":"6","key":"10.1016\/j.iliver.2025.100197_bib14","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.dld.2015.03.006","article-title":"Viral hepatitis and anti-phospholipid antibodies positivity: a systematic review and meta-analysis","volume":"47","author":"Ambrosino","year":"2015","journal-title":"Dig Liver Dis"},{"issue":"13","key":"10.1016\/j.iliver.2025.100197_bib15","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1177\/0961203315595129","article-title":"Antiphospholipid syndrome, antiphospholipid antibodies and solid organ transplantation","volume":"24","author":"Gonz\u00e1lez-Moreno","year":"2015","journal-title":"Lupus"},{"issue":"19","key":"10.1016\/j.iliver.2025.100197_bib16","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.4254\/wjh.v7.i19.2229","article-title":"Liver transplantation in a patient with primary antiphospholipid syndrome and Budd-Chiari syndrome","volume":"7","author":"Reshetnyak","year":"2015","journal-title":"World J Hepatol"},{"issue":"9","key":"10.1016\/j.iliver.2025.100197_bib17","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.3390\/jcm9092822","article-title":"Portal thrombosis in cirrhosis: role of thrombophilic disorders","volume":"9","author":"Fortea","year":"2020","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.iliver.2025.100197_bib18","doi-asserted-by":"crossref","first-page":"25","DOI":"10.15403\/jgld.2014.1121.amb","article-title":"Autoimmune liver diseases and antiphospholipid antibodies positivity: a meta-analysis of literature studies","volume":"24","author":"Ambrosino","year":"2015","journal-title":"J Gastrointestin Liver Dis"},{"issue":"1","key":"10.1016\/j.iliver.2025.100197_bib19","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/jcla.21723","article-title":"High frequency of antiphospholipid antibodies in primary biliary cirrhosis","volume":"29","author":"Manka\u00ef","year":"2015","journal-title":"J Clin Lab Anal"},{"key":"10.1016\/j.iliver.2025.100197_bib20","article-title":"Transient antiphospholipid syndrome associated with primary cytomegalovirus infection: a case report and literature review","volume":"2014","author":"Nakayama","year":"2014","journal-title":"Case Rep Rheumatol"},{"issue":"20","key":"10.1016\/j.iliver.2025.100197_bib21","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1056\/NEJMcpc079029","article-title":"Case records of the Massachusetts General Hospital. Case 35-2007. A 30-year-old man with inflammatory bowel disease and recent onset of fever and bloody diarrhea","volume":"357","author":"Babyatsky","year":"2007","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.iliver.2025.100197_bib22","doi-asserted-by":"crossref","first-page":"e470","DOI":"10.1055\/s-0041-1736289","article-title":"Evaluation of frequency, clinical correlation, and antibodies confirmation profile in patients with suspected antiphospholipid syndrome","volume":"5","author":"Martins","year":"2021","journal-title":"TH Open"},{"issue":"4","key":"10.1016\/j.iliver.2025.100197_bib23","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1177\/0961203317731532","article-title":"Risk of developing antiphospholipid antibodies following viral infection: a systematic review and meta-analysis","volume":"27","author":"Abdel-Wahab","year":"2018","journal-title":"Lupus"},{"key":"10.1016\/j.iliver.2025.100197_bib24","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1129201","article-title":"Antiphospholipid antibodies in patients with stroke during COVID-19: a role in the signaling pathway leading to platelet activation","volume":"14","author":"Capozzi","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.iliver.2025.100197_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.687534","article-title":"Antiphospholipid antibodies and infection: non Nova sed Nove","volume":"12","author":"Sciascia","year":"2021","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.iliver.2025.100197_bib26","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1046\/j.1365-2141.1998.00722.x","article-title":"Prevalence and significance of anticardiolipin, anti-beta2 glycoprotein I and anti-prothrombin antibodies in chronic hepatitis C","volume":"101","author":"Leroy","year":"1998","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.iliver.2025.100197_bib27","doi-asserted-by":"crossref","first-page":"36","DOI":"10.5045\/kjh.2011.46.1.36","article-title":"Characterization of antiphospholipid antibodies in chronic hepatitis B infection","volume":"46","author":"Huh","year":"2011","journal-title":"Korean J Hematol"},{"issue":"2","key":"10.1016\/j.iliver.2025.100197_bib28","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/hep.510230201","article-title":"Anticardiolipin antibodies in chronic hepatitis C: implication of hepatitis C virus as the cause of the antiphospholipid syndrome","volume":"23","author":"Prieto","year":"1996","journal-title":"Hepatology"},{"issue":"10","key":"10.1016\/j.iliver.2025.100197_bib29","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1111\/j.1572-0241.1999.01447.x","article-title":"Anticardiolipin antibodies in patients with liver disease","volume":"94","author":"Mangia","year":"1999","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"10.1016\/j.iliver.2025.100197_bib30","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/S0168-8278(99)80127-5","article-title":"Prevalence of hepatitis C virus infection in patients with antiphospholipid syndrome","volume":"30","author":"Mu\u00f1oz-Rodr\u00edguez","year":"1999","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.iliver.2025.100197_bib31","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1128\/CDLI.7.2.241-244.2000","article-title":"Anticardiolipin antibodies in patients with chronic hepatitis C virus infection: characterization in relation to antiphospholipid syndrome","volume":"7","author":"Ordi-Ros","year":"2000","journal-title":"Clin Diagn Lab Immunol"},{"issue":"6","key":"10.1016\/j.iliver.2025.100197_bib32","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1136\/ard.59.6.483","article-title":"Anticardiolipin autoantibodies in serum samples and cryoglobulins of patients with chronic hepatitis C infection","volume":"59","author":"Sthoeger","year":"2000","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.iliver.2025.100197_bib33","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1191\/096120300678828659","article-title":"Antiphospholipid antibodies in alcoholic liver disease are influenced by histological damage but not by alcohol consumption","volume":"9","author":"Perney","year":"2000","journal-title":"Lupus"},{"issue":"6","key":"10.1016\/j.iliver.2025.100197_bib34","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1136\/gut.49.6.852","article-title":"Antiphospholipid antibodies associated with alcoholic liver disease specifically recognise oxidised phospholipids","volume":"49","author":"Rolla","year":"2001","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.iliver.2025.100197_bib35","first-page":"293","article-title":"High prevalence of anticardiolipin antibodies in patients with HCV-associated oral lichen planus","volume":"9","author":"Nagao","year":"2002","journal-title":"Int J Mol Med"},{"issue":"7","key":"10.1016\/j.iliver.2025.100197_bib36","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1097\/01.meg.0000059140.68845.74","article-title":"Anticardiolipin antibodies in chronic hepatitis B and chronic hepatitis D infection, and hepatitis B-related hepatocellular carcinoma. Relationship with portal vein thrombosis","volume":"15","author":"Elefsiniotis","year":"2003","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.iliver.2025.100197_bib37","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41572-020-0160-6","article-title":"Immune-related adverse events of checkpoint inhibitors","volume":"6","author":"Ramos-Casals","year":"2020","journal-title":"Nat Rev Dis Primers"},{"issue":"5","key":"10.1016\/j.iliver.2025.100197_bib38","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.jhep.2009.06.023","article-title":"Thrombotic risk factors and liver histologic lesions in non-alcoholic fatty liver disease","volume":"51","author":"Papatheodoridis","year":"2009","journal-title":"J Hepatol"},{"issue":"3\/4","key":"10.1016\/j.iliver.2025.100197_bib39","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.jaut.2009.02.017","article-title":"Prevalence of hepatitis C serum antibody in autoimmune diseases","volume":"32","author":"Agmon-Levin","year":"2009","journal-title":"J Autoimmun"},{"issue":"4","key":"10.1016\/j.iliver.2025.100197_bib40","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.bpg.2013.06.016","article-title":"Liver abnormalities in connective tissue diseases","volume":"27","author":"De Santis","year":"2013","journal-title":"Best Pract Res Clin Gastroenterol"},{"issue":"5","key":"10.1016\/j.iliver.2025.100197_bib41","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1034\/j.1600-0676.2000.020005366.x","article-title":"The liver in collagen diseases: pathologic study of 160 cases with particular reference to hepatic arteritis, primary biliary cirrhosis, autoimmune hepatitis and nodular regenerative hyperplasia of the liver","volume":"20","author":"Matsumoto","year":"2000","journal-title":"Liver"},{"issue":"1","key":"10.1016\/j.iliver.2025.100197_bib42","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/0925-4439(95)00017-X","article-title":"Mitochondrial antigens, molecular mimicry and autoimmune disease","volume":"1271","author":"Baum","year":"1995","journal-title":"Biochim Biophys Acta"},{"issue":"2","key":"10.1016\/j.iliver.2025.100197_bib43","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1136\/ard.2002.001826","article-title":"Hepatic manifestations of autoimmune rheumatic diseases","volume":"63","author":"Abraham","year":"2004","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.iliver.2025.100197_bib44","article-title":"Budd-Chiari syndrome as an initial manifestation of incomplete systemic lupus erythematosus","volume":"11","author":"Porcu","year":"2024","journal-title":"Eur J Case Rep Intern Med"},{"issue":"2","key":"10.1016\/j.iliver.2025.100197_bib45","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/00042737-199802000-00011","article-title":"Autoimmune chronic active hepatitis associated with the presence of antiphospholipid antibodies","volume":"10","author":"Pathmakanthan","year":"1998","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.iliver.2025.100197_bib46","first-page":"37","article-title":"Immune components of liver damage associated with connective tissue diseases","volume":"2","author":"Chentoufi","year":"2014","journal-title":"J Clin Transl Hepatol"},{"issue":"9","key":"10.1016\/j.iliver.2025.100197_bib47","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1023\/A:1005501421242","article-title":"Autoimmune hepatitis associated with autoimmune hemolytic anemia and anticardiolipin antibody syndrome","volume":"45","author":"Gurudu","year":"2000","journal-title":"Dig Dis Sci"},{"issue":"5","key":"10.1016\/j.iliver.2025.100197_bib48","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1097\/00042737-200105000-00021","article-title":"Autoimmune hepatitis associated with the antiphospholipid syndrome","volume":"13","author":"Dourakis","year":"2001","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.iliver.2025.100197_bib49","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/00042737-200502000-00017","article-title":"Antiphospholipid syndrome in combination with autoimmune hepatitis","volume":"17","author":"Hueber","year":"2005","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"10","key":"10.1016\/j.iliver.2025.100197_bib50","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1055\/s-2001-17862","article-title":"Autoimmune hepatitis associated with coagulation disorders and immunethyreopathy","volume":"39","author":"Benten","year":"2001","journal-title":"Z Gastroenterol"},{"issue":"1","key":"10.1016\/j.iliver.2025.100197_bib51","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1196\/annals.1361.043","article-title":"Clinical relevance of antiphospholipid antibodies in primary biliary cirrhosis","volume":"1051","author":"von Landenberg","year":"2005","journal-title":"Ann N Y Acad Sci"},{"issue":"3","key":"10.1016\/j.iliver.2025.100197_bib52","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1016\/j.clinre.2018.12.002","article-title":"Autoimmune hepatitis in patients with multiple sclerosis: the role of immunomodulatory treatment","volume":"43","author":"Rigopoulou","year":"2019","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"4","key":"10.1016\/j.iliver.2025.100197_bib53","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.revmed.2006.12.005","article-title":"Auto-immune hepatitis and antiphospholipids","volume":"28","author":"Branger","year":"2007","journal-title":"Rev Med Interne"},{"issue":"10","key":"10.1016\/j.iliver.2025.100197_bib54","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1097\/MEG.0b013e32820a0035","article-title":"Autoimmune intrahepatic cholangiopathy associated with antiphospholipid antibody syndrome","volume":"19","author":"Murdaca","year":"2007","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.iliver.2025.100197_bib55","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s10875-008-9211-6","article-title":"IgA anti-b2GPI antibodies in patients with autoimmune liver diseases","volume":"28","author":"Gabeta","year":"2008","journal-title":"J Clin Immunol"},{"issue":"1","key":"10.1016\/j.iliver.2025.100197_bib56","doi-asserted-by":"crossref","first-page":"101","DOI":"10.15403\/jgld.2014.1121.cpa","article-title":"Primary biliary cirrhosis--autoimmune hepatitis overlap syndrome associated with dermatomyositis, autoimmune thyroiditis and antiphospholipid syndrome","volume":"24","author":"Pamfil","year":"2015","journal-title":"J Gastrointestin Liver Dis"},{"issue":"3","key":"10.1016\/j.iliver.2025.100197_bib57","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jaut.2005.01.016","article-title":"Prevalence and clinical significance of anticardiolipin antibodies in patients with type 1 autoimmune hepatitis","volume":"24","author":"Liaskos","year":"2005","journal-title":"J Autoimmun"},{"issue":"1","key":"10.1016\/j.iliver.2025.100197_bib58","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jhep.2015.07.040","article-title":"EASL clinical practice guidelines: vascular diseases of the liver","volume":"64","year":"2016","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.iliver.2025.100197_bib59","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1002\/hep.31646","article-title":"Vascular liver disorders, portal vein thrombosis, and procedural bleeding in patients with liver disease: 2020 practice guidance by the American Association for the Study of liver diseases","volume":"73","author":"Northup","year":"2021","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.iliver.2025.100197_bib60","doi-asserted-by":"crossref","first-page":"18","DOI":"10.14309\/ajg.0000000000000486","article-title":"ACG clinical guideline: disorders of the hepatic and mesenteric circulation","volume":"115","author":"Simonetto","year":"2020","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"10.1016\/j.iliver.2025.100197_bib61","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1538-7836.2007.02772.x","article-title":"Hypercoagulation and thrombophilia in liver disease","volume":"6","author":"Northup","year":"2008","journal-title":"J Thromb Haemost"},{"issue":"4","key":"10.1016\/j.iliver.2025.100197_bib62","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1177\/1076029610369797","article-title":"Antiphospholipid antibodies and antiphospholipid syndrome: role in portal vein thrombosis in patients with and without liver cirrhosis","volume":"17","author":"Amitrano","year":"2011","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.iliver.2025.100197_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2024.152467","article-title":"The autoimmune landscape of Porto-sinusoidal vascular disorder: what the rheumatologist needs to know","volume":"67","author":"Tonutti","year":"2024","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.iliver.2025.100197_bib64","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s10620-010-1278-2","article-title":"Non-cirrhotic intrahepatic portal hypertension: associated gut diseases and prognostic factors","volume":"56","author":"Eapen","year":"2011","journal-title":"Dig Dis Sci"},{"issue":"2","key":"10.1016\/j.iliver.2025.100197_bib65","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.jhep.2013.08.013","article-title":"Non-cirrhotic portal hypertension - diagnosis and management","volume":"60","author":"Khanna","year":"2014","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.iliver.2025.100197_bib66","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1136\/gut.51.2.275","article-title":"Idiopathic non-cirrhotic intrahepatic portal hypertension in the West: a re-evaluation in 28 patients","volume":"51","author":"Hillaire","year":"2002","journal-title":"Gut"},{"issue":"9","key":"10.1016\/j.iliver.2025.100197_bib67","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1097\/00007890-199711150-00021","article-title":"Anticardiolipin antibodies and hepatic artery thrombosis after liver transplantation","volume":"64","author":"Pascual","year":"1997","journal-title":"Transplantation"},{"issue":"2","key":"10.1016\/j.iliver.2025.100197_bib68","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/S0002-9270(02)05888-4","article-title":"Antiphospholipid antibodies before and after liver transplantation","volume":"98","author":"Van Thiel","year":"2003","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"10.1016\/j.iliver.2025.100197_bib69","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/ctr.12682","article-title":"The dynamic and clinical significance of autoantibodies and immunoglobulins in liver transplant recipients","volume":"30","author":"Stanca","year":"2016","journal-title":"Clin Transplant"},{"issue":"2","key":"10.1016\/j.iliver.2025.100197_bib70","doi-asserted-by":"crossref","first-page":"667","DOI":"10.3390\/jcm12020667","article-title":"Antiphospholipid syndrome in renal allograft Recipients-A long-term multicenter analysis","volume":"12","author":"Furma\u0144czyk-Zawiska","year":"2023","journal-title":"J Clin Med"},{"issue":"4","key":"10.1016\/j.iliver.2025.100197_bib71","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/j.transproceed.2018.02.034","article-title":"Prevalence of antiphospholipid antibody positivity and association of pretransplant lupus anticoagulant positivity with early allograft dysfunction in liver transplantation","volume":"50","author":"Kwon","year":"2018","journal-title":"Transplant Proc"},{"issue":"5","key":"10.1016\/j.iliver.2025.100197_bib72","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1016\/j.transproceed.2013.01.024","article-title":"The significance of antiphospholipid antibodies in liver recipients","volume":"45","author":"Furma\u0144czyk-Zawiska","year":"2013","journal-title":"Transplant Proc"},{"issue":"6","key":"10.1016\/j.iliver.2025.100197_bib73","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1160\/TH04-12-0839","article-title":"Antibody profiles for the diagnosis of antiphospholipid syndrome","volume":"93","author":"Pengo","year":"2005","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.iliver.2025.100197_bib74","doi-asserted-by":"crossref","first-page":"468","DOI":"10.3389\/fimmu.2018.00468","article-title":"Pretransplant IgA-Anti-Beta 2 glycoprotein I antibodies as a predictor of early graft thrombosis after renal transplantation in the clinical practice: a multicenter and prospective study","volume":"9","author":"Morales","year":"2018","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.iliver.2025.100197_bib75","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1097\/TP.0000000000001199","article-title":"The presence of pretransplant antiphospholipid antibodies IgA Anti-\u03b2-2-Glycoprotein I as a predictor of graft thrombosis after renal transplantation","volume":"101","author":"Morales","year":"2017","journal-title":"Transplantation"},{"issue":"8","key":"10.1016\/j.iliver.2025.100197_bib76","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.autrev.2011.10.014","article-title":"Thromboprophylaxis in carriers of antiphospholipid antibodies (APL) without previous thrombosis: \u201cpros\u201d and \u201cCons.\u201d","volume":"11","author":"Ceccarelli","year":"2012","journal-title":"Autoimmun Rev"},{"issue":"1","key":"10.1016\/j.iliver.2025.100197_bib77","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.autrev.2014.09.002","article-title":"Bridging therapy in antiphospholipid syndrome and antiphospholipid antibodies carriers: case series and review of the literature","volume":"14","author":"Raso","year":"2015","journal-title":"Autoimmun Rev"},{"issue":"7","key":"10.1016\/j.iliver.2025.100197_bib78","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1007\/s00296-017-3727-0","article-title":"Perioperative management of patients with antiphospholipid syndrome: a single-center experience","volume":"37","author":"Atisha-Fregoso","year":"2017","journal-title":"Rheumatol Int"},{"issue":"7","key":"10.1016\/j.iliver.2025.100197_bib79","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1007\/s11926-014-0426-7","article-title":"Perioperative management of antiphospholipid antibody-positive patients","volume":"16","author":"Saunders","year":"2014","journal-title":"Curr Rheumatol Rep"},{"issue":"2","key":"10.1016\/j.iliver.2025.100197_bib80","doi-asserted-by":"crossref","first-page":"146","DOI":"10.4103\/0971-9784.81571","article-title":"Antiphospholipid syndrome, cardiac surgery and cardiopulmonary bypass","volume":"14","author":"Sharma","year":"2011","journal-title":"Ann Card Anaesth"},{"issue":"1","key":"10.1016\/j.iliver.2025.100197_bib81","doi-asserted-by":"crossref","DOI":"10.1177\/0300060519896889","article-title":"Anaesthetic considerations for patients with antiphospholipid syndrome undergoing non-cardiac surgery","volume":"48","author":"Kim","year":"2020","journal-title":"J Int Med Res"},{"issue":"4","key":"10.1016\/j.iliver.2025.100197_bib82","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1053\/jpsu.2001.22315","article-title":"Living donor liver transplantation for Budd-Chiari syndrome with inferior vena cava obstruction and associated antiphospholipid antibody syndrome","volume":"36","author":"Yasutomi","year":"2001","journal-title":"J Pediatr Surg"},{"issue":"7","key":"10.1016\/j.iliver.2025.100197_bib83","doi-asserted-by":"crossref","first-page":"796","DOI":"10.6002\/ect.2020.0331","article-title":"Living donor liver transplant in patients with budd-chiari syndrome: a single-center experience at our university hospital","volume":"18","author":"Obed","year":"2020","journal-title":"Exp Clin Transplant"},{"issue":"5","key":"10.1016\/j.iliver.2025.100197_bib84","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1213\/XAA.0000000000000551","article-title":"Liver transplantation in a patient with antiphospholipid syndrome: a case report","volume":"9","author":"Steckelberg","year":"2017","journal-title":"A A Case Rep"},{"issue":"7","key":"10.1016\/j.iliver.2025.100197_bib85","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1007\/s10067-019-04483-8","article-title":"The efficacy and safety of antithrombotic therapy in patients with positive antiphospholipid antibodies receiving invasive procedures: experience from a single tertiary center","volume":"38","author":"Chen","year":"2019","journal-title":"Clin Rheumatol"},{"issue":"10","key":"10.1016\/j.iliver.2025.100197_bib86","doi-asserted-by":"crossref","DOI":"10.1097\/TXD.0000000000001214","article-title":"Case report: perioperative management of combined coronary artery bypass grafting, liver and kidney transplantation in a patient with antiphospholipid syndrome","volume":"7","author":"Garvanovic","year":"2021","journal-title":"Transplant Direct"},{"issue":"6","key":"10.1016\/j.iliver.2025.100197_bib87","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1053\/jlts.2003.50082","article-title":"Repeated graft loss caused by recurrent hepatic artery thrombosis after liver transplantation","volume":"9","author":"Vivarelli","year":"2003","journal-title":"Liver Transpl"},{"key":"10.1016\/j.iliver.2025.100197_bib88","article-title":"Catastrophic antiphospholipid syndrome after orthotopic liver transplant","volume":"2022","author":"Okeke","year":"2022","journal-title":"Case Rep Transplant"},{"issue":"5","key":"10.1016\/j.iliver.2025.100197_bib89","first-page":"785","article-title":"Anticardiolipin antibody-associated cerebral infarction in cirrhosis: clearance of anticardiolipin antibody after liver transplantation","volume":"89","author":"Talenti","year":"1994","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"10.1016\/j.iliver.2025.100197_bib90","doi-asserted-by":"crossref","DOI":"10.5492\/wjccm.v13.i4.96074","article-title":"Thrombotic complications post liver transplantation: etiology and management","volume":"13","author":"Srivastava","year":"2024","journal-title":"World J Crit Care Med"},{"issue":"7","key":"10.1016\/j.iliver.2025.100197_bib91","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1097\/TP.0000000000001240","article-title":"Patterns of early allograft dysfunction in adult live donor liver transplantation: the A2ALL experience","volume":"100","author":"Pomposelli","year":"2016","journal-title":"Transplantation"},{"issue":"7","key":"10.1016\/j.iliver.2025.100197_bib92","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1191\/0961203303lu394oa","article-title":"Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines","volume":"12","author":"Asherson","year":"2003","journal-title":"Lupus"},{"issue":"12","key":"10.1016\/j.iliver.2025.100197_bib93","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/j.autrev.2016.09.010","article-title":"Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of 500 patients from the International CAPS Registry","volume":"15","author":"Rodr\u00edguez-Pint\u00f3","year":"2016","journal-title":"Autoimmun Rev"},{"issue":"5","key":"10.1016\/j.iliver.2025.100197_bib94","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.jclinane.2010.07.007","article-title":"Devastating intracardiac and aortic thrombosis: a case report of apparent catastrophic antiphospholipid syndrome during liver transplantation","volume":"23","author":"Gologorsky","year":"2011","journal-title":"J Clin Anesth"},{"issue":"2","key":"10.1016\/j.iliver.2025.100197_bib95","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1191\/0961203303lu278cr","article-title":"Catastrophic antiphospholipid syndrome complicating orthotopic liver transplantation","volume":"12","author":"Villamil","year":"2003","journal-title":"Lupus"},{"issue":"9","key":"10.1016\/j.iliver.2025.100197_bib96","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1111\/jth.15417","article-title":"Effect of heparanase inhibitor on tissue factor overexpression in platelets and endothelial cells induced by anti-\u03b22-GPI antibodies","volume":"19","author":"Capozzi","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"1","key":"10.1016\/j.iliver.2025.100197_bib97","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-14946-0","article-title":"Heparanase and macrophage interplay in the onset of liver fibrosis","volume":"7","author":"Secchi","year":"2017","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.iliver.2025.100197_bib98","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1002\/path.1554","article-title":"Heparanase expression during normal liver development and following partial hepatectomy","volume":"203","author":"Goldshmidt","year":"2004","journal-title":"J Pathol"},{"issue":"1","key":"10.1016\/j.iliver.2025.100197_bib99","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-91777-0","article-title":"Heparanase inhibition preserves the endothelial glycocalyx in lung grafts and improves lung preservation and transplant outcomes","volume":"11","author":"Noda","year":"2021","journal-title":"Sci Rep"},{"issue":"8","key":"10.1016\/j.iliver.2025.100197_bib100","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0200877","article-title":"Heparan sulfate is a plasma biomarker of acute cellular allograft rejection","volume":"13","author":"Barbas","year":"2018","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.iliver.2025.100197_bib101","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1538-7836.2007.02772.x","article-title":"Coagulation in liver disease group. Hypercoagulation and thrombophilia in liver disease","volume":"6","author":"Northup","year":"2008","journal-title":"J Thromb Haemost"}],"container-title":["iLIVER"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772947825000556?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772947825000556?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T04:07:09Z","timestamp":1765598829000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772947825000556"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":101,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S2772947825000556"],"URL":"https:\/\/doi.org\/10.1016\/j.iliver.2025.100197","relation":{},"ISSN":["2772-9478"],"issn-type":[{"value":"2772-9478","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"From thrombosis to transplantation: The role of anti-phospholipid antibodies in liver disease management","name":"articletitle","label":"Article Title"},{"value":"iLIVER","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.iliver.2025.100197","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd on behalf of Tsinghua University Press.","name":"copyright","label":"Copyright"}],"article-number":"100197"}}